Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5632-5642

  Garcia, Marta ^a   Fernandez Garcia, Nuria Isabel ^b   Rivas, Veronica ^b   Carretero, Marta ^a   Escamez, Maria J ^a   Gonzalez Martin, Alicia ^b   Medrano, Estela E ^c   Volpert, Olga ^d   Jorcano, Jose L ^a   Jimenez, Benilde ^b   Larcher, Fernando ^a   Del Rio, Marcela ^a  

^a CIEMAT   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; NEUROTROPHIC FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR;

ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER MORTALITY; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; EYE PROTEINS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; PROTEIN BIOSYNTHESIS; PROTEINS; SERPINS; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4143109252     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0230     Document Type: Article

References (44)

1. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
2. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559-70.
3. Dredge K, Dalgleish AG, Marriott JB. Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 2003;4:667-74.
4. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
5. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22:3172-9.
6. Li G, Satyamoorthy K, Meier F, et al. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003;22:3162-71.
7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
8. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003;4:628-36.
9. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001;98:2593-7.
10. Crawford SE, Stellmach V, Ranalli M, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001;114:4421-8.
11. Abramson LP, Stellmach V, Doll JA, et al. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg 2003;38:336-42.
12. Wang L, Schmitz V, Perez-Mediavilla A, et al. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003;8:72-9.
13. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-80.
14. Jaffe E, Nachman RL, Becker CG, Minick RC. Culture of human endothelial cells derived from umbilical veins. Circulation 1972;46:211-53.
15. Reed JA, Bales E, Xu W, et al. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res 2001;61:8074-8.
16. Chen D, Xu W, Bales E, et al. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003;63:6626-34.
17. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996;7:1405-13.
18. Yang S, Delgado R, King S, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 1999;10:123-32.
19. Larcher F, Del Rio M, Serrano F, et al. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocytes grafts. FASEB J 2001;15:1529-38.
20. Del Rio M, Larcher F, Serrano F, et al. A preclinical model for the analysis of genetically modified human skin in vivo. Hum Gene Ther 2002;20:959-68.
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
22. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of a naturally occurring inhibitor of angiogenesis. Methods Enzymol 1991;198:440-50.
23. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
24. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003;17:529-31.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
26. Church GM, Gilbert W. Genome sequencing. Proc Natl Acad Sci USA 1984;81:1991-5.
27. Xu W, Angelis K, Danielpour D, et al. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci USA 2000;97:5924-9.
28. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (Wash DC) 1999;285:245-8.
29. Zhu Z, Sanchez-Sweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 2001;61:1707-16.
30. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002;8:330-4.
31. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;97:11205-10.
32. Yamagishi S, Amano S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003;65:186-90.
33. Yamagishi S, Inagaki Y, Amano S, et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002;296:877-82.
34. Guan M, Pang CP, Yam HF, et al. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther 2004;11:325-32.
35. Alberdi E, Hyde CC, Becerra SP. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry 1998;37:10643-52.
36. Bilak MM, Becerra SP, Vincent AM. et al. Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons J Neurosci 2002;22:9378-86.
37. Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem 2002;277:45400-7.
38. Alberdi E, Aymerich MS, Becerra SP. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem 1999;274:31605-12.
39. Aymerich MS, Alberdi EM, Martinez A, Becerra SP. Evidence for pigment epithelium-derived factor receptors in the neural retina. Investig Ophthalmol Vis Sci 2001;42:3287-93.
40. Liu H, Ren JG, Cooper WL, et al. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004;101:6605-10.
41. Mahtabifard A, Merritt RE. Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003;126:28-38.
42. Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004;164:1225-32.
43. Uehara H, Miyamoto M, Kato K, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004;64:3533-7.
44. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene 2003;22:3070-5.